1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Demographic and clinical characteristics for patients with HSP and the control groupa
Patients with HSP (n = 12)Healthy Controls (n = 12)P Value
Age at MRI (yr)50 (49 ± 8)48 (48 ± 5).5b
Sex (female)50%67%.4c
Disease duration (yr)23 (24 ± 16)––
Disease onset (yr)23 (25 ± 18)––
Spastic gate loci
    SPG108% (1)
    SPG3a8% (1)
    SPG458% (7)
    SPG7+SPG48% (1)
    SPG517% (2)
  • ↵a Values are median, mean ± SD, or No. (%). Numbers after percentages are frequencies.
  • ↵b Wilcoxon test.
  • ↵c Pearson test.